A novel tumour suppressor protein encoded by circMAPK14 inhibits progression and metastasis of colorectal cancer by competitively binding to MKK6.


Journal

Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971

Informations de publication

Date de publication:
10 2021
Historique:
revised: 24 09 2021
received: 25 05 2021
accepted: 28 09 2021
entrez: 28 10 2021
pubmed: 29 10 2021
medline: 22 2 2022
Statut: ppublish

Résumé

The mitogen-activated protein kinase (MAPK) pathway is highly associated with the progression and metastasis of various solid tumours. MAPK14, a core molecule of the MAPK pathway, plays vital roles in the colorectal cancer (CRC). Recent studies have shown that circRNAs can affect tumour progression by encoding peptides. However, little is known regarding the potential protein translated from circMAPK14 and whether it plays a role in the carcinogenesis of colorectal cancer. The RNA level and translatable potential of circMAPK14 in CRC was verified using qRT-PCR and public databases. RNase R digestion assay, qRT-PCR, sanger sequencing and FISH assays were utilised to verify the circular characteristics and subcellular localisation of circMAPK14. The suppressive role of circMAPK14 on the progression and metastasis of CRC was verified in vivo and in vitro. LC/MS analysis combined with western blotting demonstrated the presence and relative expression of circMAPK14-175aa. The underlying mechanism of circMAPK14-175aa action to inhibit CRC was identified by co-IP analysis. The binding of U2AF2 within the flanking introns of circMAPK14 was evaluated by RNA pull-down assay and RIP assay. Ultimately, luciferase reporter gene assays and ChIP assays confirmed that FOXC1 suppressed transcription of U2AF2 by binding to the U2AF2 promoter in the -400 bp to -100 bp region.  RESULTS: We identified that hsa_circ_0131663 (termed circMAPK14) showed significantly decreased expression level in cells and tissue samples of CRC, and was primarily localised in the cytoplasm. A series of function experiments demonstrated that circMAPK14 influenced CRC progression and metastasis by encoding a peptide of 175 amino acids (termed circMAPK14-175aa). We also found that circMAPK14-175aa reduced nuclear translocation of MAPK14 by competitively binding to MKK6, thus facilitating ubiquitin-mediated degradation of FOXC1. Moreover, we described a positive feedback loop in CRC in which elevated FOXC1 expression was caused by reduced circMAPK14-175aa expression. This, in turn, decreased circMAPK14 biogenesis by suppressing U2AF2 transcription. In summary, we reported for the first time that circMAPK14 functioned as a tumour-suppressor by encoding circMAPK14-175aa, which blocked the progression and metastasis of colorectal cancer.

Sections du résumé

BACKGROUND
The mitogen-activated protein kinase (MAPK) pathway is highly associated with the progression and metastasis of various solid tumours. MAPK14, a core molecule of the MAPK pathway, plays vital roles in the colorectal cancer (CRC). Recent studies have shown that circRNAs can affect tumour progression by encoding peptides. However, little is known regarding the potential protein translated from circMAPK14 and whether it plays a role in the carcinogenesis of colorectal cancer.
METHODS
The RNA level and translatable potential of circMAPK14 in CRC was verified using qRT-PCR and public databases. RNase R digestion assay, qRT-PCR, sanger sequencing and FISH assays were utilised to verify the circular characteristics and subcellular localisation of circMAPK14. The suppressive role of circMAPK14 on the progression and metastasis of CRC was verified in vivo and in vitro. LC/MS analysis combined with western blotting demonstrated the presence and relative expression of circMAPK14-175aa. The underlying mechanism of circMAPK14-175aa action to inhibit CRC was identified by co-IP analysis. The binding of U2AF2 within the flanking introns of circMAPK14 was evaluated by RNA pull-down assay and RIP assay. Ultimately, luciferase reporter gene assays and ChIP assays confirmed that FOXC1 suppressed transcription of U2AF2 by binding to the U2AF2 promoter in the -400 bp to -100 bp region.  RESULTS: We identified that hsa_circ_0131663 (termed circMAPK14) showed significantly decreased expression level in cells and tissue samples of CRC, and was primarily localised in the cytoplasm. A series of function experiments demonstrated that circMAPK14 influenced CRC progression and metastasis by encoding a peptide of 175 amino acids (termed circMAPK14-175aa). We also found that circMAPK14-175aa reduced nuclear translocation of MAPK14 by competitively binding to MKK6, thus facilitating ubiquitin-mediated degradation of FOXC1. Moreover, we described a positive feedback loop in CRC in which elevated FOXC1 expression was caused by reduced circMAPK14-175aa expression. This, in turn, decreased circMAPK14 biogenesis by suppressing U2AF2 transcription.
CONCLUSION
In summary, we reported for the first time that circMAPK14 functioned as a tumour-suppressor by encoding circMAPK14-175aa, which blocked the progression and metastasis of colorectal cancer.

Identifiants

pubmed: 34709743
doi: 10.1002/ctm2.613
pmc: PMC8516360
doi:

Substances chimiques

Biomarkers, Tumor 0
Cell-Free Nucleic Acids 0
Mitogen-Activated Protein Kinase 14 EC 2.7.11.24
MAP Kinase Kinase 6 EC 2.7.12.2
MAP2K6 protein, human EC 2.7.12.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e613

Informations de copyright

© 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

Références

Cell Rep. 2015 Jan 13;10(2):170-7
pubmed: 25558066
Cancers (Basel). 2019 Oct 16;11(10):
pubmed: 31623173
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Nat Rev Drug Discov. 2017 Aug;16(8):525-526
pubmed: 28529321
Ann Oncol. 2017 Nov 1;28(11):2780-2785
pubmed: 29045529
Elife. 2021 Jan 21;10:
pubmed: 33476259
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Cell Res. 2017 May;27(5):626-641
pubmed: 28281539
Mol Cancer. 2017 May 23;16(1):94
pubmed: 28535767
Nat Rev Cancer. 2009 Aug;9(8):537-49
pubmed: 19629069
Nat Cell Biol. 2021 Mar;23(3):278-291
pubmed: 33664496
Cancer Cell. 2014 Apr 14;25(4):484-500
pubmed: 24684847
J Biol Chem. 1998 Jan 16;273(3):1741-8
pubmed: 9430721
Neuro Oncol. 2021 May 5;23(5):743-756
pubmed: 33325513
Mol Cancer. 2021 Feb 3;20(1):26
pubmed: 33536039
Mol Cell. 2014 Oct 2;56(1):55-66
pubmed: 25242144
Pharmacol Ther. 2021 Apr;220:107715
pubmed: 33141028
Science. 1995 Apr 21;268(5209):415-7
pubmed: 7536344
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mol Cancer. 2020 Dec 14;19(1):172
pubmed: 33317550
Mol Ther. 2021 May 5;29(5):1683-1702
pubmed: 33484969
Nat Cell Biol. 2014 Jul;16(7):685-94
pubmed: 24880666
Eur J Med Chem. 2021 Mar 5;213:113216
pubmed: 33524689
Mol Cell Biol. 1996 Mar;16(3):1247-55
pubmed: 8622669
Lancet Oncol. 2005 May;6(5):322-7
pubmed: 15863380
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Nat Commun. 2018 Jul 6;9(1):2629
pubmed: 29980667
Mol Cancer. 2020 Feb 4;19(1):22
pubmed: 32019587
Mol Cancer. 2019 Aug 30;18(1):131
pubmed: 31470874
Cancer Biol Med. 2021 Mar 12;:
pubmed: 33710802
J Pathol. 2020 Feb;250(2):217-230
pubmed: 31650548
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
J Biol Chem. 2002 Mar 22;277(12):10292-7
pubmed: 11782474
Gut. 2020 Apr;69(4):748-763
pubmed: 32034004
Annu Rev Biochem. 2017 Jun 20;86:193-224
pubmed: 28460188
Oncogene. 2019 Jan;38(4):483-496
pubmed: 30171256
Genome Biol. 2019 Apr 26;20(1):84
pubmed: 31027518

Auteurs

Lu Wang (L)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Jiahui Zhou (J)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Chuan Zhang (C)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Ranran Chen (R)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Qingyang Sun (Q)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Peng Yang (P)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Chaofan Peng (C)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Yuqian Tan (Y)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Chi Jin (C)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Tuo Wang (T)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Jiangzhou Ji (J)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Yueming Sun (Y)

Division of Colorectal Surgery, Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH